U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07897409) titled 'The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity' on Oct. 03.
Brief Summary: Breast cancer is one of the world's most common cancers in females. Most of the chemotherapy protocols used to treat breast cancer involve doxorubicin. Doxorubicin has a very significant antitumor effect on breast tumors. One of the obstacles that hinders the use of doxorubicin is cardiotoxicity. Although many agents are used to address this issue, only dexrazoxane is FDA-approved. One suggested pathway for doxorubicin-induced cardiotoxicity is due to calcium imbalance. Calcium ions are very important in controlling th...